Zomedica Announces Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference
10 Septembre 2020 - 12:55PM
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary
health company creating point-of-care diagnostics products for
companion animals, announced today that Robert Cohen, Interim Chief
Executive Officer, and Stephanie Morley, President and Chief
Medical Officer, will present at the upcoming H.C. Wainwright
Virtual Global Investment Conference. The presentation is scheduled
for September 14, 2020 at 4:00 pm ET.
The slides to be presented by Mr. Cohen and Dr. Morley will be
accessible through the Investors section of the Company's website
at www.zomedica.com the morning of the presentation.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a
veterinary health company creating products for companion animals
(canine, feline and equine) by focusing on the unmet needs of
clinical veterinarians. Zomedica’s product portfolio will include
innovative diagnostics and therapeutics that emphasize patient
health and practice health. With a team that includes clinical
veterinary professionals, it is Zomedica’s mission to provide
veterinarians the opportunity to lower costs, increase
productivity, and grow revenue while better serving the animals in
their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts:
http://investors.zomedica.com
- LinkedIn:
https://www.linkedin.com/company/zomedica
- Facebook:
https://www.facebook.com/zomedica/
- Twitter:
https://twitter.com/zomedica
Investor Relations Contact:PCG Advisory
GroupKirin Smith, COOksmith@pcgadvisory.com+1
646.863.6519www.pcgadvisory.com
Media Contact:Meredith
Newmanmnewman@zomedica.com +1 734.369.2555 ext. 119
Zomedica Pharmaceuticals (TSXV:ZOM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Zomedica Pharmaceuticals (TSXV:ZOM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about Zomedica Pharmaceuticals Corp (TSX Venture Exchange): 0 recent articles
Plus d'articles sur